Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1845 1
1908 1
1916 1
1925 1
1941 1
1944 1
1945 2
1946 3
1947 2
1948 3
1949 1
1950 6
1951 9
1952 5
1953 4
1954 9
1955 7
1956 5
1957 3
1958 12
1959 5
1960 6
1961 2
1962 5
1963 2
1964 9
1965 7
1966 6
1967 8
1968 15
1969 18
1970 11
1971 7
1972 15
1973 8
1974 13
1975 14
1976 11
1977 11
1978 14
1979 15
1980 12
1981 12
1982 16
1983 19
1984 22
1985 23
1986 23
1987 13
1988 13
1989 16
1990 21
1991 18
1992 23
1993 24
1994 22
1995 20
1996 13
1997 19
1998 13
1999 16
2000 17
2001 23
2002 23
2003 21
2004 16
2005 22
2006 25
2007 33
2008 38
2009 47
2010 51
2011 44
2012 53
2013 68
2014 75
2015 75
2016 69
2017 86
2018 82
2019 94
2020 85
2021 106
2022 98
2023 86
2024 84
2025 76

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,945 results

Results by year

Filters applied: . Clear all
Page 1
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. Among authors: chapman ab. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
Glucose-sensitive insulin with attenuation of hypoglycaemia.
Hoeg-Jensen T, Kruse T, Brand CL, Sturis J, Fledelius C, Nielsen PK, Nishimura E, Madsen AR, Lykke L, Halskov KS, Koščová S, Kotek V, Davis AP, Tromans RA, Tomsett M, Peñuelas-Haro G, Leonard DJ, Orchard MG, Chapman A, Invernizzi G, Johansson E, Granata D, Hansen BF, Pedersen TA, Kildegaard J, Pedersen KM, Refsgaard HHF, Alifrangis L, Fels JJ, Neutzsky-Wulff AV, Sauerberg P, Slaaby R. Hoeg-Jensen T, et al. Among authors: chapman a. Nature. 2024 Oct;634(8035):944-951. doi: 10.1038/s41586-024-08042-3. Epub 2024 Oct 16. Nature. 2024. PMID: 39415004 Free PMC article.
Linking vaccine adjuvant mechanisms of action to function.
Ben-Akiva E, Chapman A, Mao T, Irvine DJ. Ben-Akiva E, et al. Among authors: chapman a. Sci Immunol. 2025 Feb 14;10(104):eado5937. doi: 10.1126/sciimmunol.ado5937. Epub 2025 Feb 14. Sci Immunol. 2025. PMID: 39951545 Review.
Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians.
Gartlehner G, Dobrescu A, Chapman A, Toromanova A, Emprechtinger R, Persad E, Affengruber L, Pieh C, Klerings I, Wagner G. Gartlehner G, et al. Among authors: chapman a. Ann Intern Med. 2023 Feb;176(2):196-211. doi: 10.7326/M22-1845. Epub 2023 Jan 24. Ann Intern Med. 2023. PMID: 36689750 Free article.
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.
Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Cornec-Le Gall E, Drenth JPH, Gansevoort RT, Harris PC, Harris T, Horie S, Liebau MC, Liew M, Mallett AJ, Mei C, Mekahli D, Odland D, Ong ACM, Onuchic LF, Pei YP, Perrone RD, Rangan GK, Rayner B, Torra R, Balk EM, Gordon CE, Earley A, Mustafa RA, Devuyst O. Torres VE, et al. Among authors: chapman ab. Kidney Int. 2025 Feb;107(2):234-254. doi: 10.1016/j.kint.2024.07.010. Kidney Int. 2025. PMID: 39848746 Free article.
Risk factors for type 1 and type 2 myocardial infarction.
Wereski R, Kimenai DM, Bularga A, Taggart C, Lowe DJ, Mills NL, Chapman AR. Wereski R, et al. Among authors: chapman ar. Eur Heart J. 2022 Jan 13;43(2):127-135. doi: 10.1093/eurheartj/ehab581. Eur Heart J. 2022. PMID: 34431993 Free PMC article. Clinical Trial.
1,945 results